(Q39333811)

English

Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

1 reference

based on heuristic

inferred from title

author name string

Brett H Simmons

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Joseph H Lee

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Kush Lalwani

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Anand Giddabasappa

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Brittany A Snider

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Anthony Wong

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Patrick B Lappin

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Jeetendra Eswaraka

8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Julie L Kan

9

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

James G Christensen

10

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Farbod Shojaei

11

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

publication date

9 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

70

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

213-220

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

The PIK-related kinases intercept conventional signaling pathways

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

RAS Interaction with PI3K: More Than Just Another Effector Pathway

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

Ras, PI(3)K and mTOR signalling controls tumour cell growth

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

The PI3K pathway as drug target in human cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

Current status of developments and applications of micro-CT.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-012-1899-6

21 January 2018

Identifiers

10.1007/S00280-012-1899-6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39333811&oldid=2202788158"